Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01918670
Other study ID # FrenchAFAblationSurvey
Secondary ID
Status Active, not recruiting
Phase N/A
First received August 6, 2013
Last updated August 6, 2013
Start date November 2010
Est. completion date December 2013

Study information

Verified date August 2013
Source Clinique Pasteur
Contact n/a
Is FDA regulated No
Health authority France: no authority.
Study type Observational [Patient Registry]

Clinical Trial Summary

Atrial fibrillation is the most frequent sustained arrhythmia. Catheter ablation is a procedure that is currently used for the treatment of symptomatic atrial fibrillation patients.

We have organized a multi-centric national survey of catheter ablation of atrial fibrillation in order to have a feedback on the type of procedures being performed and the overall results (freedom of atrial fibrillation) over an average follow-up of 18 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date December 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- all patients undergoing catheter ablation of atrial fibrillation or left atrial flutter

Exclusion Criteria:

- patients undergoing catheter ablation of other types of arrhythmia

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
catheter ablation of atrial fibrillation
electric pulmonary vein disconnection

Locations

Country Name City State
France Clinique Pasteur Toulouse

Sponsors (6)

Lead Sponsor Collaborator
Clinique Pasteur Nouvelle Clinique Nantaise, Nantes, France, Parly 2 Medical Surgical Center (CMC), Le Chesnay, France, Rennes University Hospital, University Hospital of Grenoble, Grenoble, France, University Hospital of Rouen, Rouen, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Atrial fibrillation relapse Documentation of atrial fibrillation relapse (symptomatic or asymptomatic) after the first 3 months after the index procedure starting 3 months after the procedure till an average of 18months follow-up No
Secondary Early atrial fibrillation relapse Documented atrial fibrillation relapse (symptomatic or asymptomatic) in the first 3 months after the index procedure first 3 months No